ViroMed Co Ltd (084990):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:ViroMed Co Ltd (084990) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8016
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:韓国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
ViroMed Co Ltd (ViroMed), formerly ViroMedica Pacific Inc is a biotechnology company that discovers and develops biopharmaceuticals and phytotherapeutics for human diseases. The company provides therapeutic drugs such as therapeutic angiogenesis for cardiovascular diseases, therapeutic cancer vaccine and protein based therapeutic thrombocytopenia. Its pipeline products include VM501, VM202 and VM206. ViroMed’s therapeutic drugs target diseases such as thrombocytopenia, breast cancer, ovarian cancer, critical limb ischemia, painful diabetic peripheral neuropathy, angina pectoris, ischemic heart failure and amyotrophic lateral sclerosis, among others. The company also develops botanical and nutraceutical products. It operates in South Korea, China and the US. ViroMed is headquartered in Seoul, South Korea.

ViroMed Co Ltd (084990) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
ViroMed Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ViroMed Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
ViroMed Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ViroMed Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
ViroMed Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
ViroMed Co Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
ViroMed Enters into Agreement with Reyon Pharmaceutical 10
Licensing Agreements 11
Bluebird bio Enters Into Licensing Agreement With ViroMed 11
Viromed Enters Into Licensing Agreement With Reyon Pharma For Hepatitis B Vaccine 12
Equity Offering 13
ViroMed to Raise USD159.8 Million in Rights Offering of Shares 13
ViroMed to Raise USD12.8 Million in Private Placement of Shares 14
ViroMed Announces Private Placement Of Shares For US$10 Million 15
Acquisition 16
Reyon Pharma Sells its Stake in ViroMed for USD108 Million 16
ViroMed Co Ltd – Key Competitors 17
ViroMed Co Ltd – Key Employees 18
ViroMed Co Ltd – Locations And Subsidiaries 19
Head Office 19
Recent Developments 20
Product News 20
11/09/2017: ViroMed Builds Team of Experts to Complete New Global Drug Development 20
02/09/2017: VM BioPharma Announces Publication of Phase 1/2 Clinical Data of Novel Gene Therapy VM202 in Amyotrophic Lateral Sclerosis (ALS) 21
Product Approvals 22
Oct 30, 2017: VM BioPharma Announces Generic Name “donaperminogene seltoplasmid” for Investigational Novel Gene Therapy, VM202 22
Clinical Trials 23
Sep 25, 2017: ViroMed, Gene Therapy Powerhouse on Global Stage 23
Aug 03, 2017: VM BioPharma Announces First Patient Dosed in Phase 3 Study of Gene Therapy Candidate VM202 for Non-Healing Diabetic Foot Ulcers 24
Appendix 25
Methodology 25
About GlobalData 25
Contact Us 25
Disclaimer 25

List of Tables
ViroMed Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
ViroMed Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ViroMed Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
ViroMed Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ViroMed Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
ViroMed Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
ViroMed Enters into Agreement with Reyon Pharmaceutical 10
Bluebird bio Enters Into Licensing Agreement With ViroMed 11
Viromed Enters Into Licensing Agreement With Reyon Pharma For Hepatitis B Vaccine 12
ViroMed to Raise USD159.8 Million in Rights Offering of Shares 13
ViroMed to Raise USD12.8 Million in Private Placement of Shares 14
ViroMed Announces Private Placement Of Shares For US$10 Million 15
Reyon Pharma Sells its Stake in ViroMed for USD108 Million 16
ViroMed Co Ltd, Key Competitors 17
ViroMed Co Ltd, Key Employees 18

List of Figures
ViroMed Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
ViroMed Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
ViroMed Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
ViroMed Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
ViroMed Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ViroMed Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
ViroMed Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ViroMed Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[ViroMed Co Ltd (084990):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Longfor Properties Co., Ltd.:戦略・SWOT・企業財務分析
    Longfor Properties Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Longfor Properties Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • PT Astra International Tbk:企業の戦略・SWOT・財務情報
    PT Astra International Tbk - Strategy, SWOT and Corporate Finance Report Summary PT Astra International Tbk - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Intec Pharma Ltd (NTEC):製薬・医療:M&Aディール及び事業提携情報
    Summary Intec Pharma Ltd (Intec Pharma) is a biopharmaceutical company that offers delivery solutions for drugs. The company’s pipeline products include drug indications for Parkinson’s disease, insomnia and other diseases. Its proprietary gastro retentive formulation, offers a drug delivery solutio …
  • Plus Therapeutics Inc (PSTV):企業の財務・戦略的SWOT分析
    Plus Therapeutics Inc (PSTV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Parkland Fuel Corp (PKI):石油・ガス:M&Aディール及び事業提携情報
    Summary Parkland Fuel Corp (Parkland) is a downstream energy company. It markets various fuel and petroleum products, including gasoline, propane, lubricants, diesel, heating oil, and other petroleum products. The company maintains a portfolio of supply relationships, storage infrastructure, and thi …
  • Meta Biomed Co Ltd (059210):企業の製品パイプライン分析2018
    Summary Meta Biomed Co Ltd (Meta Biomed) is a medical device company that develops and manufactures dental materials and equipments. The company provides suture, dental, bone and medical products. It offers various medical products such as endodontic materials, bone restorative materials, implant ma …
  • Neuland Laboratories Ltd (NEULANDLAB):企業の財務・戦略的SWOT分析
    Summary Neuland Laboratories Ltd (Neuland Lab), a subsidiary of Neuland Health Sciences Pvt Ltd is an API manufacturing service provider that manufactures active pharmaceutical ingredients, advanced intermediates; and offers chemistry related services. The company provides APIs in various therapeuti …
  • Genesis Energy:企業の戦略・SWOT・財務情報
    Genesis Energy - Strategy, SWOT and Corporate Finance Report Summary Genesis Energy - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Inivata Ltd:医療機器:M&Aディール及び事業提携情報
    Summary Inivata Ltd (Inivata) is a cancer genomics company that harnesses liquid biopsy platform to enhance personalized healthcare in oncology. The company’s product portfolio includes InVisionFirst – Lung, which offers advanced sequencing technology to detect copy number variants, single nucleotid …
  • Ming Fai International Holdings Limited:企業の戦略・SWOT・財務情報
    Ming Fai International Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Ming Fai International Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …
  • SYNNEX Corp (SNX):企業の財務・戦略的SWOT分析
    SYNNEX Corp (SNX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Marquette Capital Partners LLC:企業の戦略・SWOT・財務情報
    Marquette Capital Partners LLC - Strategy, SWOT and Corporate Finance Report Summary Marquette Capital Partners LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Hunan Fangsheng Pharmaceutical Co Ltd (603998):製薬・医療:M&Aディール及び事業提携情報
    Summary Hunan Fangsheng Pharmaceutical Co Ltd (Fangsheng Pharma) is a research-based comprehensive pharmaceutical enterprise offers research, development, manufacturing and sales of pharmaceuticals. The enterprise’ products include tablets, capsules, granules, oral suspension, powder, suppository, p …
  • Ana Holdings Inc:企業の戦略・SWOT・財務情報
    Ana Holdings Inc - Strategy, SWOT and Corporate Finance Report Summary Ana Holdings Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Nippon Chemiphar Co Ltd (4539):企業の財務・戦略的SWOT分析
    Summary Nippon Chemiphar Co Ltd (Nippon Chemiphar) is a provider of pharmaceutical drugs and health-related services. The company manufactures, supplies, imports and exports ethical pharmaceuticals and diagnostic agents. Nippon Chemiphar offers diagnostic products, such as IgE NC, a diagnostic kit t …
  • Hess Corp Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    Hess Corp Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary Hess Corp (Hess) is a global independent energy company which carries out the exploration and production of crude oil and natural gas. It primarily operates in US, Denmark, the Joint Development Area of Ma …
  • Coutts & Co:企業の戦略・SWOT・財務情報
    Coutts & Co - Strategy, SWOT and Corporate Finance Report Summary Coutts & Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Electro Scientific Industries Inc (ESIO):企業の財務・戦略的SWOT分析
    Summary Electro Scientific Industries Inc (ESI) is a brand of MKS Instruments Equipment & Solutions Division, which offers laser-based manufacturing solutions. The company offers products such as flex interconnect, circuit packaging, high density interconnect, automation, scribbing and grooving, mem …
  • Ana Holdings Inc
    Ana Holdings Inc - Strategy, SWOT and Corporate Finance Report Summary Ana Holdings Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • TSUM Trading House:企業の戦略的SWOT分析
    TSUM Trading House - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆